Skip to content
Open access

PET/CT with Gold Nanoparticle Contrast Enhancement as a Method for Evaluating the Anatomical and Physiological Parameters of B16F10 Melanoma Tumor Model

Oct 2026 · Journal of oncology: diagnostic radiology and radiotherapy · 0 citations · 24 references

Abstract

Introduction : Hybrid positron emission tomography and computed tomography (PET/CT) is widely used in experimental oncology; however, on native CT images, tumor tissue is indistinguishable from normal soft tissues. Contrast agents based on gold nanoparticles (AuNPs) have been proposed to address this issue. Purpose : To experimentally validate the use of AuNPs as a CT contrast agent for PET/CT imaging of subcutaneous and intracranial B16F10 tumor models. Materials and methods : AuNPs with a 6 ± 2 nm gold core were synthesized by laser ablation and coated with polyethylene glycol. C57Bl/6 mice with subcutaneous B16F10 melanoma (n = 5) received AuNPs intravenously at a dose of 940 ± 30 mg Au/kg; PET/CT with 18 F-FDG was performed at 1, 3, and 5 days post-injection. The control group (n = 5) received no AuNPs and underwent PET/CT at the same time points. Three mice with intracranial melanoma B16F10 underwent PET/CT 24 hours after AuNP injection (680 ± 40 mg Au/kg). Radiodensity (HU), SUV max , SUV mean , and tumor volume were assessed. Results : In the subcutaneous tumor, AuNPs accumulated predominantly at the periphery of the lesion: radiodensity increased from 97 ± 12 HU to 274 ± 61 HU at day 1 and to 345 ± 120 HU at day 5. This enabled clear delineation of tumor borders and measurement of anatomical volume. In the intracranial model, AuNPs were uniformly distributed throughout the tumor, increasing radiodensity from 137 ± 9 HU to 236 ± 28 HU. In the subcutaneous tumor, a trend toward increased SUV max and SUV mean was observed in the experimental group at days 1–3 post-injection (p = 0.06–0.08), presumably associated with the activation of tumor-associated macrophages phagocytosing the nanoparticles. Conclusion : 18 F-FDG PET/CT with AuNP contrast enhancement allows simultaneous assessment of tumor metabolic activity and precise anatomical borders and can be recommended for in vivo studies in experimental oncology.

Read PDF

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.